Laurie Heilmann Named President of New CrownBio Global Life Science and Diagnostic Solutions Division
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, today announces the appointment of Laurie Heilmann as President of CrownBio Global Life Science Product and Diagnostic Solutions. Heilmann will lead the newly formed division to achieve its mission of enabling scientists to access, discover and develop revolutionary drugs and diagnostics by providing cutting-edge solutions that transform scientific ideas into reality.
"Laurie is a dynamic and visionary leader with an impressive record of success building and accelerating innovative biotechnology companies on a global scale," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "As President of CrownBio Global Life Science and Diagnostic Solutions Division, Laurie will spearhead strategy development and commercialization of a unique portfolio of products and services that supports clinical and diagnostic markets across several therapeutic concentrations, including oncology, inflammation, cardiovascular, metabolic and neurological diseases."
"This is an exciting opportunity to propel CrownBio Global Life Science and Diagnostic Solutions to a market leader position in life science and diagnostic spaces," said Laurie Heilmann, former Chief Business Officer at Crown Bioscience. "It is a pivotal time in the industry as we move forward with game-changing products and services that support research from concept through commercialization and enable scientists to access, discover and develop innovative drugs and diagnostics across several therapeutic areas."
Laurie possesses a diverse therapeutic background and has over three decades of global experience aligning sales and marketing with R&D to steer company strategy. As President of CrownBio Life Science Products and Diagnostics, Laurie will be responsible for charting new inroads of scientific and technological advancements to meet the needs of clinical and diagnostic markets across several therapy areas.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Hexagon Composites ASA: Mandatory Notification of Trade5.6.2020 17:11:41 CEST | Press release
Dan Krick, SVP Organizational Development has sold 24,896 shares in Hexagon Composites ASA at a price of NOK 36,42 per share. The sale is primarily to finance tax obligations from his exercise of options earlier in the year. After the transaction Dan Krick holds zero shares in Hexagon Composites ASA. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For more information: David Bandele, CFO, Hexagon Composites ASA Telephone: +47 920 91 483 | firstname.lastname@example.org About Hexagon Composites Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications.
CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS5.6.2020 15:05:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2020-06-12 Maturity dateLoanISIN codeCouponVolume, SEK million2026-11-121059 SE00071259271.00 %1,000 +/- 2502031-05-12 1062 SE00139353190.125 %1,000 +/- 250 Settlement date 2020-06-16 Bids have to be entered by 10.00 on JUN 12, 2020 Highest permitted bid volume: 1 000 SEK million in issue SGB 1059 and 1 000 SEK million in issue SGB 1062 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON JUN 12, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved athttp://www.riksbank.se
Correction: Correction: Correction: AB Klaipedos nafta financial information reporting dates in 20205.6.2020 15:05:00 CEST | Press release
Correction: AB Klaipedos nafta social responsibility report for the year 2019 will be released on 9 June 2020. AB Klaipedos nafta (further – KN) informs that it plans to release financial information in 2020 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2020KN preliminary revenues* for the previous month31 January 2020Interim financial information for the year 20196 April 2020Audited financial statements for the year 201929 April 2020Interim financial information for the 1st quarter of 20209 June 2020Social responsibility report for the year 201931 July 2020Interim financial information for the 6 month of 202030 October 2020Interim financial information for the 3 quarters of 2020 On 28 April 2020, the Company plans to convene an Ordinary General Meeting of Shareholders. * It should be noted that from 2020 the company will be adjusting course of releasing monthly financial information. As range of the services provided to the
Medtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe5.6.2020 15:00:10 CEST | Press release
DUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx. The approval is the first of its kind globally. Resolute Onyx DES is available for use in the United States, as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States. Data have been submitted to the FDA with the intent of obtainin
Conditions for Riksbank Bid Procedures Sek Covered Bonds5.6.2020 15:00:00 CEST | Press release
Conditions for Riksbank Bid Procedures Sek Bonds Sveriges Riksbank Bid procedure details Covered Bonds, 2020-06-11 Maturity dateLoanISIN codeCouponVolume, SEK million2022-04-08 5531 SE00069912461.00 %1,000 +/- 5002021-12-15 574 SE00081034771.50 %1,000 +/- 500 2021-12-151585SE00089925151.50 %1,000 +/- 5002022-06-15191SE00075256541.00 %1,000 +/- 5002021-12-152112SE00104947161.00 %400 +/- 2502021-09-15514SE00065433281.75 %400 +/- 2502022-06-15143SE00085866551.25 %400 +/- 250 Settlement date 2020-06-15 Bids have to be entered by 10.00 on JUN 11 2020 Highest permitted bid volume: 1,000 SEK million in issue 5531 1,000 SEK million in issue 574 1,000 SEK million in issue 1585 1,000 SEK million in issue 191 400 SEK million in issue 2112 400 SEK million in issue 514 400 SEK million in issue 143 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON JUN 11, 2020. For more information,
AB Klaipėdos nafta preliminary revenue for the May 20205.6.2020 15:00:00 CEST | Press release
AB Klaipėdos nafta, (further the Company) reviewed operating segments since the beginning of the second quarter of 2020 and presents revenue disclosures accordingly. The following operating segments of the Company are: Oil terminals activity, that includes Klaipėda oil terminal and Subačius oil terminal,Regulated LNG activity in Klaipėda andCommercial LNG activity, that includes small-scale LNG reloading station in Klaipėda and Business development projects. The preliminary sales revenue of the Company’s oil terminals for the May 2020 comprised EUR 3.1 million and is higher by EUR 0.8 million or by 34.8 per cent compared to May of 2019. The preliminary sales revenue is higher due to increase of sales of oil products storage, if compared to the same period of 2019. The preliminary sales revenue of the Company’s oil terminals for the first five months of 2020 comprised EUR 13.7 million, i.e. higher by 6.2 per cent, compared to the same period of 2019. The preliminary sales revenue of the